文献速递妇科

使用扩展基因分型与细胞学对HPV阳性结果进行风险分层:Onclarity试验基线期数据

Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
PubMed 文献 · Gynecol Oncol · 2023-05-05

Onclarity试验基线期纳入33858人,其中2978例HPV阳性,评估扩展HPV基因分型(xGT)联合细胞学对≥CIN3的风险分层性能,并与IMPACT试验中HPV16/18联合p16/Ki-67双染(DS)的数据进行ROC比较。结果显示xGT与HPV初筛联合DS对高级别CIN的检测性能相似,xGT能灵活可靠地按不同指南的阴道镜转诊阈值进行风险分层。

要点

  • xGT联合细胞学可将HPV阳性者按≥CIN3风险分层,风险从>LSIL的39.4%到HPV45/35/39/68/51/56/59/66且NILM的0.6%。
  • ≥CIN3的ROC分析中,最佳截断点约在非HPV16但HPV18或31任意细胞学(灵敏度85.9%,阴道镜转诊至≥CIN3比7.4)与非HPV16/18/31但HPV33/58/52且NILM(灵敏度94.5%,比值10.8)之间。
  • HPV16/18联合DS分流灵敏度94.3%,阴道镜转诊至≥CIN3比为11.4,xGT性能与之相似。

核心结论

  • xGT与HPV初筛联合DS对高级别CIN的检测性能相似。
  • xGT能灵活可靠地按不同指南或组织设定的阴道镜风险阈值进行风险分层。

研究设计与样本

  • Onclarity试验基线期纳入33858人,其中2978例HPV阳性。
  • 采用ROC分析比较xGT联合细胞学与IMPACT试验已发表的HPV16/18联合DS数据。

主要发现

  • 共检出163例≥CIN3。
  • ≥CIN3风险分层(风险百分比)为:>LSIL 39.4%;HPV16且≤LSIL 13.3%;HPV18/31且≤LSIL 5.9%;HPV33/58/52/45且ASC-US/LSIL 2.4%;HPV33/58/52且NILM 2.1%;HPV35/39/68/51/56/59/66且ASC-US/LSIL 0.9%;HPV45/35/39/68/51/56/59/66且NILM 0.6%。
  • ≥CIN3的ROC分析中,非HPV16但HPV18或31任意细胞学:灵敏度85.9%,阴道镜转诊至≥CIN3比7.4;非HPV16/18/31但HPV33/58/52且NILM:灵敏度94.5%,比值10.8。
  • HPV16/18联合DS分流:灵敏度94.3%,阴道镜转诊至≥CIN3比11.4。

关键数值与推荐

  • xGT风险分层阈值包括:>LSIL、HPV16且≤LSIL、HPV18/31且≤LSIL、HPV33/58/52/45且ASC-US/LSIL、HPV33/58/52且NILM、HPV35/39/68/51/56/59/66且ASC-US/LSIL、HPV45/35/39/68/51/56/59/66且NILM。
  • ≥CIN3的ROC最佳截断点约在非HPV16但HPV18或31任意细胞学(灵敏度85.9%,比值7.4)与非HPV16/18/31但HPV33/58/52且NILM(灵敏度94.5%,比值10.8)之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimizing the balance between colposcopy referrals and the detection of high-grade cervical intraepithelial neoplasia (CIN) during cervical cancer screening requires robust triage strategies. We evaluated the performance of extended HPV genotyping (xGT), in combination with cytology triage, and compared it to previously published performance data for high-grade CIN detection by HPV16/18 primary screening in combination with p16/Ki-67 dual staining (DS). METHODS AND MATERIALS: The baseline phase of the Onclarity trial enrolled 33,858 individuals, yielding 2978 HPV-positive participants. Risk values for ≥CIN3 were determined for Onclarity result groupings corresponding to HPV16, not HPV16 but HPV18 or 31, not HPV16/18/31 but HPV33/58 or 52, not HPV16/18/31/33/58/52 but HPV35/39/68 or 45 or 51 or 56/59/66 across all cytology categories. Published data from the IMPACT trial for HPV16/18 plus DS was utilized as a comparator during ROC analyses. RESULTS: There were 163 ≥ CIN3 cases detected. The ≥CIN3 risk stratum hierarchy (% risk of ≥CIN3) that resulted from this analysis included: >LSIL (39.4%); HPV16, ≤LSIL (13.3%); HPV18/31, ≤LSIL (5.9%); HPV33/58/52/45, ASC-US/LSIL (2.4%); HPV33/58/52, NILM (2.1%); HPV35/39/68/51/56/59/66, ASC-US/LSIL (0.9%); and HPV45/35/39/68/51/56/59/66, NILM (0.6%). For ≥CIN3 ROC analysis, the optimal cutoff for sensitivity versus specificity was approximated between not HPV16 but HPV18 or 31, any cytology (≥CIN3 sensitivity = 85.9% and colposcopy-to- ≥ CIN3 = 7.4) and not HPV16/18/31 but HPV33/58/52, NILM (≥CIN3 sensitivity = 94.5% and colposcopy-to- ≥CIN3 = 10.8). HPV16/18 with DS triage showed a sensitivity of 94.3%, with a colposcopy-to- ≥ CIN3 ratio of 11.4. CONCLUSIONS: xGT performed similarly compared to HPV primary screening plus DS for detection of high-grade CIN. xGT provides results that stratify risk in a flexible and reliable manner for colposcopy risk thresholds set by different guidelines or organizations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stoler MH, Parvu V, Yanson K, et al. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial. Gynecol Oncol. 2023. PMID: 37149907. doi:10.1016/j.ygyno.2023.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。